This NLSDays 2020 Pre-Event will be a private, by-invitation only event. Participants will arrive in Malmö one day prior to NLSDays to experience a full-day program alongside relevant industry and financial parties. The day will include interactive workshops, educational sessions, discussions, and pitches, etc.
Moderator(s): Ms. Helena Strigård - Director General, SwedenBIO
Mr. Olivier Duchamp - Managing Director, NLSDays - NLS Invest Mr. Emmanuel Ligner - CEO & President at Cityva (former GE Healthcare Life Sciences) Mr. Erik Gatenholm - CEO and Co-Founder, Cellink Dr. Rafiq Hasan - CEO, ExACT Therapeutics
The Nordic countries hold a unique position. With health data covering more than 27 million people, we can become a world-leading health innovation hub for the benefit of patients and society. However, in order to realise this ambition, we must cooperate to better align, integrate, and use our health data in a protected and patient-centric way that also supports industry participation. If we collaborate, we can learn from each other and overcome the challenges together. In this session, leaders from across the Nordic Region will discuss successful collaboration models related to health data as a driver for innovation and development, with recommendations for joint action.
Ms. Rajji Mehdwan - General Manager, Roche Norway Dr. Lars Lindsköld - Portfolio manager, Sweper / Swelife Dr. Nikolai Brun - Chair HMA-EMA Taskforce on Big Data Ms. Louise Rosenlund Nielsen - Head of International Development & Partnerships, CopCap Dr. Mervi Aavikko - Project Manager FinnGen, University of Helsinki Mr. Bogi Eliasen - Director of Health, Copenhagen Institute for Futures Studies Dr. Frederik Knud Nielsen - Strategic Pipeline Lead, Nordics, Novartis
The human microbiome is considered to be a counterpart to the human genome, with the number of genes in our microbiome outnumbering the genes in our genome by 100 to 1. We also know that understanding and thus balancing our microbiome is vital to human health and that our microbes are impacted on a community, rather than individual, level.
In this session, “Microbiome: the New Genetics?” hosted by the Greater Copenhagen Microbiome Signature Project, we will hear from some of the world’s leaders on the current developments within microbiome research, such as host-microbe interactions and their implications on disease progression and treatment, where opportunities and challenges exist in translating proof-of-concept studies in animal models to clinical trials, and how research can transition from academia to industry to result in improved therapies and better therapeutic outcomes for patients.
The discussions will further shed light on how the Nordics can play a key role in moving the field forward.
Moderator(s): Dr. Eric De La Fortelle - Venture Partner, Seventure Partners
Dr. Mirjam Mol-Arts - Chief Science and Medical Officer, Ferring Pharmaceuticals Dr. Henrik Bjørn Nielsen - Chief Scientific Officer, Clinical Microbiomics Dr. Gianfranco Grompone - Chief Scientific Officer, BioGaia Ms. Sarah Lidé - Senior Strategy & Project Manager, Medicon Valley Alliance Dr. Paul Ross - Director, APC Microbiome Ireland
Our world has seen an emergence and re-emergence of infectious and contagious diseases, albeit rather controlled and isolated outbreaks – until now. COVID-19 has propelled us into a new era, one in which the impacts of globalization, travel, and climate change on our collective health and safety are evident. Many new questions are now upon us:
In this session, we will tackle as much as we can, given what we know & are continuing to learn.
While our life science industry is full of exciting innovations, many companies are wary of shouting about their accomplishments, both culturally and in such a strictly regulated environment. At the same time, the world won’t notice your company unless you provide compelling information about who you are and how you are changing the game.
It’s vital that potential stakeholders understand that you are developing the best solution to the problems they face. Therefore, you must be able to present them with the bold vision behind what your innovation means to the market, alongside a relevant brand story.
Join us in this interactive fireside chat to learn about the power of branding in differentiating you from your competitors and in influencing customer perceptions through storytelling.
Approaching the financial community can be a daunting task, one made greater if we haven’t learned the specificities and expectations of potential investors. Just as identifying the right match & coming prepared are essential to maximizing chance of success, did you also know that receiving a rejection can be a good thing? How so, you ask? Join this session, where leading life science investors give insights on what they look for and what to know – beyond the obvious – including subtleties, overall fit, and vision. In addition, we have brought together a brilliant, all-female panel that will tackle some of today’s vs tomorrow’s realities in life sciences and will dialogue interactively to answer audience questions. We will take this opportunity to explore gender roles in investments & corporate leadership. In 2015, NY Times quoted, “There are more CEOs named John than female CEOs.” Today, we see increasing numbers of female partners in VC firms, but has it been enough? Likewise, how might women think and invest differently – or do they? And what does gender diversity in company leadership say about its potential valuation or success – and does this all even apply to the Nordics? Expect a great dialogue and come prepared with questions!
Moderator(s): Dr. Sonia Benhamida - Senior Vice President Healthcare, DNB
Dr. Ingrid Teigland Akay - Managing Partner, Hadean Ventures Dr. Christina Trojel-Hansen - CEO and Co-Founder - Oscine Therapeutics, in Residence - Arch Venture Partners Ms. Jeanne Bolger - Corporate Venture Capital Investor, Johnson & Johnson Innovation
Tackling global health challenges requires that we move from ‘reactive’ to ‘proactive’ care, and that we personalize our approach. The practice of evidence-based medicine and the continued identification of new biomarkers are vital steps in improving disease diagnosis, improving the safety and efficacy of existing medicines, and in developing new medicines and targeted therapies. In this session, we discuss the needs and challenges from both industry and financial viewpoints.
Ms. Karin Conde-Knape - CVP Global Diabetes, Cardio-Renal and Global Drug Discovery, Novo Nordisk Ms. Carolina Haefliger - VP, Head Centre for Genomics Research, AstraZeneca Dr. Patrick Sobocki - Investment Manager, Industrifonden
In the world of exponential data and digital disruption, there are more stakeholders involved in R&D than ever before. Traditional business models across the drug discovery and development value chain are transitioning at an increasingly rapid pace. Likewise, the diversification of product pipelines has expanded beyond drugs to increasingly include medical devices, big data, and digital tools, through which we can better engage patients and harness the best of medicine. In this session, we take a look at this new field: who is involved, how are they working together, and what does this mean for the future of clinical trials from Academic, Pharma, MedTech, and Regulatory perspectives?
Mr. Martin Olovsson - CEO and Co-Founder, Ondosis Dr. Magnus Björsne - CEO, Astrazeneca BioVentureHub Dr. Jessica Shull - European Lead, Digital Therapeutics Alliance Dr. Sam Oddsson - Chief Medical Officer & Co-Founder, SidekickHealth Dr. Elisabeth Liljensten - CEO, Devicia Mr. Torbjörn Hägglöf - Artificial Intelligence Business Sales & Delivery Executive, Cognitive Business Solutions, IBM Global Business Services Ms. Sofia Nordgren - Director of Regulatory Affairs, Devicia